Seattle, Aug. 29, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global immune checkpoint inhibitors market is estimated to be valued at US$ 1,444.7 million in 2022 and is expected to exhibit a CAGR of 13.2% during the forecast period (2022-2030).
Key Trends and Analysis of the Global Immune Checkpoint Inhibitors Market:
Increasing Research and development activities by key players in immune checkpoint inhibitors market is expected to drive the global immune checkpoint inhibitors market growth. For instance, in 2018, Oncolytics Biotech, Inc. announced research collaboration with the Keck School of Medicine of University of Southern California (USC), in order to develop a combination therapy of Reolycin (Oncolytics Biotech’s product), Keytruda, Velcade, and dexamethasone for the treatment of multiple myeloma in May 2018. Furthermore, in January 2018, Keytruda, developed by Merck & Co. reported slow liver cancer progression in Phase 2 trial. Immuno-oncology combination therapies are also under research for various cancer indications.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2560
Key Market Takeaways:
The global immune checkpoint inhibitors market is expected to exhibit a CAGR of 13.2% during the forecast period due to the increasing research and development activities by the key players in the market. For instance, in March 2021, Bristol Myers Squibb, pharmaceutical company, carried out research and development, and announced primary results from the Phase 2/3 RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab) versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma. The trial met its primary endpoint of progression-free survival (PFS). Follow up for overall survival, a secondary endpoint, is ongoing. The fixed-dose combination was well-tolerated. These are the first Phase 3 data to be reported from a trial evaluating an anti-LAG-3 antibody. Relatlimab is the third distinct checkpoint inhibitor (anti-PD-1, anti-CTLA-4 and anti-LAG-3) for Bristol Myers Squibb and, with Opdivo, the first fixed-dose combination to demonstrate a benefit for patients. Hence, immune checkpoint inhibitors alone or in combination have transformed treatment and improved survival rates for patients with metastatic or unresectable melanoma were studied by Bristol Myers Squibb. Lymphocyte-activation gene 3 (LAG-3) is a cell-surface molecule expressed on effector T cells and regulatory T cells (Tregs). LAG-3 regulates an inhibitory immune checkpoint pathway that limits the activity of T cells, leading to an impaired ability to attack tumor cells.
Among region, the North America segment is expected to dominate the segment growth over the forecast period, owing to the increased prevalence of Cancer which is increasing need for immune checkpoint inhibitors. For instance, in June 2021, according to data published by the National Center for Biotechnology Information, Because of the growth and aging of the US population, we predict that the annual number of cancer cases will increase 49%, from 1,534,500 in 2015 to 2,286,300 in 2050, with the largest percentage increase among adults aged ≥75 years. In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.
Competitive Landscape:
Key players operating in the global immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2560
Market Segmentation:
- Global Immune Checkpoint Inhibitors Market, By Drug Class:
- Programmed Death Receptor-1 (PD-1) Inhibitors
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Cemiplimab (Libtayo)
- Others
- Programmed Death-Ligand 1 (PD-L1) Inhibitors
- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)
- Durvalumab (Imfinzi)
- CTL-4 Checkpoint Inhibitor
- Ipilimumab (Yervoy)
- Indoleamine-2,3-dioxygenase (IDO) Inhibitors
- Lymphocyte-Activation Gene 3 Inhibitors
- Programmed Death Receptor-1 (PD-1) Inhibitors
- Global Immune Checkpoint Inhibitors Market, By Cancer Type:
- Lung Cancer
- Head & Neck Cancer
- Skin Cancer (Melanoma and Merkel Cell Carcinoma)
- Blood Cancer (Lymphoma)
- Bladder Cancer (Urothelial Carcinoma)
- Renal/Kidney Cancer
- Colorectal Cancer
- Breast Cancer
- Others
- Global Immune Checkpoint Inhibitors Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Immune Checkpoint Inhibitors Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- By Region/Country
- North America
Related Market Intelligence Reports:
Recombinant Protein Market, by Product Type (Hormones, Growth Factors, Cytokines, Plasma Protein Factor, Recombinant Metabolic Enzymes, Immune Checkpoint Regulators, and Others), by Application (Drug Discovery & Development, Biopharmaceutical Production, Basic Research, and Others), by End User (Biopharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030
Epigenetics Drugs & Diagnostic Technologies Market, By Type (Epigenetic Drugs (DNMT Inhibitors (Azacitidine, Decitabine), HDAC Inhibitors (Vorinostat, Romidepsin)), Epigenetics Diagnostic Technologies (DNA Methylation, ChIP Technology)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
